PetIQ Stock Forecast, Price & News

PetIQ (NASDAQ:PETQ) Frequently Asked Questions

Is PetIQ a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PetIQ in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PetIQ stock.
View analyst ratings for PetIQ or view top-rated stocks.

How has PetIQ's stock been impacted by COVID-19 (Coronavirus)?

PetIQ's stock was trading at $22.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PETQ shares have decreased by 9.7% and is now trading at $20.40.
View which stocks have been most impacted by COVID-19.

When is PetIQ's next earnings date?

PetIQ is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for PetIQ.

How were PetIQ's earnings last quarter?

PetIQ, Inc. (NASDAQ:PETQ) posted its earnings results on Wednesday, November, 3rd. The company reported $0.01 EPS for the quarter, meeting the Zacks' consensus estimate of $0.01. The firm had revenue of $210.53 million for the quarter, compared to analysts' expectations of $194.90 million. PetIQ had a positive trailing twelve-month return on equity of 7.36% and a negative net margin of 1.36%.
View PetIQ's earnings history.

What price target have analysts set for PETQ?

3 brokerages have issued 12-month target prices for PetIQ's shares. Their forecasts range from $30.00 to $36.00. On average, they anticipate PetIQ's stock price to reach $32.67 in the next year. This suggests a possible upside of 60.1% from the stock's current price.
View analysts' price targets for PetIQ or view top-rated stocks among Wall Street analysts.

Who are PetIQ's key executives?

PetIQ's management team includes the following people:

• McCord Christensen, Chairman & Chief Executive Officer (LinkedIn Profile)
• Susan Sholtis, President (LinkedIn Profile)
• Chad Lyon, Senior Vice President-Operations
• Zvi Glasman, Chief Financial Officer
• Lauren Olavessen, Chief Medical Officer & Senior Vice President

What is Cord Christensen's approval rating as PetIQ's CEO?

10 employees have rated PetIQ CEO Cord Christensen on Glassdoor.com. Cord Christensen has an approval rating of 89% among PetIQ's employees.

Who are some of PetIQ's key competitors?

Some companies that are related to PetIQ include Bactolac Pharmaceutical (BTCA), Medizone International (MZEIQ), Trxade Group (TRXD), TRxADE HEALTH (MEDS), Bioasis Technologies (BIOAF), Aceto (ACETQ), China Medicine (CHME), China BCT Pharmacy Group (CNBI), Chugai Pharmaceutical (CHGCY) and ScripsAmerica (SCRCQ).
View all of PETQ's competitors.

What other stocks do shareholders of PetIQ own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PetIQ investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Exelixis (EXEL), Intel (INTC), CVS Health (CVS), QUALCOMM (QCOM), Editas Medicine (EDIT) and Gilead Sciences (GILD).

When did PetIQ IPO?

(PETQ) raised $86 million in an initial public offering on Friday, July 21st 2017. The company issued 5,700,000 shares at $14.00-$16.00 per share. Jefferies and William Blair served as the underwriters for the IPO and Oppenheimer, Raymond James and SunTrust Robinson Humphrey were co-managers.

What is PetIQ's stock symbol?

PetIQ trades on the NASDAQ under the ticker symbol "PETQ."

Who are PetIQ's major shareholders?

PetIQ's stock is owned by a variety of institutional and retail investors. Top institutional investors include Nepsis Inc. (1.31%), AMI Asset Management Corp (0.55%), Nordea Investment Management AB (0.17%), AE Wealth Management LLC (0.16%), TRH Financial LLC (0.08%) and Cutler Group LP (0.00%). Company insiders that own PetIQ stock include John Newland, Mark L First, Mccord Christensen, Michael A Smith, Michael A Smith, Robert Michael Herrman, Ronald Kennedy, Susan Sholtis and Will Santana.
View institutional ownership trends for PetIQ.

Which institutional investors are selling PetIQ stock?

PETQ stock was sold by a variety of institutional investors in the last quarter, including AMI Asset Management Corp, TRH Financial LLC, AE Wealth Management LLC, and Cutler Group LP. Company insiders that have sold PetIQ company stock in the last year include John Newland, Mark L First, Mccord Christensen, Michael A Smith, Robert Michael Herrman, Ronald Kennedy, and Susan Sholtis.
View insider buying and selling activity for PetIQ or view top insider-selling stocks.

Which institutional investors are buying PetIQ stock?

PETQ stock was bought by a variety of institutional investors in the last quarter, including Nepsis Inc., and Nordea Investment Management AB. Company insiders that have bought PetIQ stock in the last two years include Mccord Christensen, Michael A Smith, Robert Michael Herrman, and Susan Sholtis.
View insider buying and selling activity for PetIQ or or view top insider-buying stocks.

How do I buy shares of PetIQ?

Shares of PETQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PetIQ's stock price today?

One share of PETQ stock can currently be purchased for approximately $20.40.

How much money does PetIQ make?

PetIQ has a market capitalization of $599.92 million and generates $780.05 million in revenue each year. The company earns $-77.47 million in net income (profit) each year or ($0.46) on an earnings per share basis.

How many employees does PetIQ have?

PetIQ employs 2,072 workers across the globe.

What is PetIQ's official website?

The official website for PetIQ is www.petiq.com.

Where are PetIQ's headquarters?

PetIQ is headquartered at 923 S. Bridgeway Pl., EAGLE ID, 83616.

How can I contact PetIQ?

PetIQ's mailing address is 923 S. Bridgeway Pl., EAGLE ID, 83616. The company can be reached via phone at (208) 939-8900 or via email at [email protected].